Hemoadsorption therapy in severe rhabdomyolysis: a report from the international, prospective COSMOS (CytOSorb ® TreatMent of Critically ill PatientS) registry
Authors:
Open Access
- 15 December 2025
- journal article
- research article
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2600720
Abstract
Severe rhabdomyolysis is associated with an increased risk of acute kidney injury (AKI) and mortality. Hemoadsorption may reduce myoglobin levels and mitigate AKI. The COSMOS registry is a prospective, multicenter, observational study evaluating hemoadsorption with CytoSorb® (CS) in critically ill patients. Consecutive eligible patients are enrolled without preselection, and data collected at multiple timepoints: 24 h before CS; during CS and 24 h post-treatment; at ICU and at hospital discharge and at 90-day follow-up. The current analysis examined the effects of hemoadsorption in patients with severe rhabdomyolysis (e.g. myoglobin > 10,000 µg/L) by comparing changes in myoglobin and creatinine levels over time and the associated clinical impact. A total of 31 patients (mean age 55 years; 19% female) were included; CS was either integrated into renal replacement therapy (RRT) (n = 25, 81%) or used in stand-alone hemoperfusion mode (n = 6, 19%). When comparing pre- to post- CS treatment, significant reductions in mean myoglobin (24,109 ± 28,777 to 4,251 ± 4,399 µg/L; p = 0.001) and creatinine levels (3.5 ± 2.9 to 2.4 ± 1.5 mg/dL; p = 0.013) were observed. ICU mortality occurred in 8 (26%) patients. All survivors (n = 23) were able to be discharged from ICU without renal support. During the 90-day follow-up only one of these patients required dialysis again. Furthermore, there were no serious device-related adverse effects reported. The current study suggests that hemoadsorption is an effective method to rapidly and safely reduce myoglobin levels in severe rhabdomyolysis and may improve kidney function. These encouraging results will require validation in larger, controlled studies.Keywords
Funding Information
- CytoSorbents Corporation and CytoSorbents Medical Inc.
This publication has 22 references indexed in Scilit:
- Mechanistic Considerations and Pharmacokinetic Implications on Concomitant Drug Administration During CytoSorb TherapyCritical Care Explorations, 2022
- Serum myoglobin as predictor of acute kidney injury and 90-day mortality in patients with rhabdomyolysis after exertional heatstroke: an over 10-year intensive care surveyInternational Journal of Hyperthermia, 2022
- Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb®)—A case reportClinical Case Reports, 2022
- Admission serum myoglobin and the development of acute kidney injury after major traumaAnnals of Intensive Care, 2021
- Rhabdomyolysis: Revisited2021
- The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney DamageInternational Journal of Molecular Sciences, 2021
- Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysisCritical Care, 2021
- Cytosorb™ in a Patient with Legionella Pneumonia–Associated RhabdomyolysisASAIO Journal, 2015
- Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical reviewCritical Care, 2014
- RhabdomyolysisChest, 2013